Algert Global’s Inhibikase Therapeutics IKT Stock Holding History

Algert Global’s Portfolio IKT Stock Details IKT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-133,830	Closed	-$225K	–	1328
2026 Q1	$225K	Buy	+133,830	New	+$238K	﹤0.01%	1062

Other funds holding IKT

Sands Capital Ventures Arlington, Virginia $614M AUM 19.92% 1-Year Est. Return

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

Trails Edge Capital Partners Atlanta, Georgia $630M AUM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Blackstone Inc New York $39B AUM 18.55% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Algert Global's IKT Position: Q2 2026 in Review

Algert Global sold out of Inhibikase Therapeutics (IKT) in Q2 2026, closing a stake of 133,830 shares — an estimated $225K sold.

Algert Global first reported a position in IKT in Q1 2026 and held it in 1 quarter. The position peaked at $225K in Q1 2026. 105 funds tracked by Wall St. Rank hold IKT as of Q2 2026.

Algert Global reported no remaining Inhibikase Therapeutics position as of Q2 2026 after selling out during the quarter.
Algert Global sold 133,830 Inhibikase Therapeutics shares in Q2 2026, an estimated $225K.
Algert Global first reported a position in Inhibikase Therapeutics in Q1 2026 and held it in 1 quarter.
Algert Global's Inhibikase Therapeutics position peaked at $225K in Q1 2026.
105 funds tracked by Wall St. Rank held Inhibikase Therapeutics as of Q2 2026.

Based on Algert Global's 13F filing for Q2 2026, filed 13 Aug 2026.